Skip to main content
Premium Trial:

Request an Annual Quote

EMBL-EBI Researchers Establish Greedy Strategy as Favorable Method to Choose Next Organism for Sequencing

NEW YORK, Nov. 25 (GenomeWeb News) - 

European Molecular Biology Laboratory-European Bioinformatics Institute scientists demonstrate in research published today in the journal PLoS Genetics that choosing the single best candidate organism for sequencing is as informative a strategy as choosing several organisms ahead of time, the institute said in a statement.


"Our findings have clear implications for planning large-scale genome sequencing efforts", said EMBL-EBI researcher and author of the paper, Fabio Pardi, in a statement. "Provided that they remain open about their choices so that two different sequencing centers don't choose the same genome, selecting the next most attractive organism to sequence is just as effective as having a long-term strategy," he said.


The tendency has been for centers to choose a group of new genomes to sequence, but employing the "greedy" strategy, as it is known by computer scientists, will most likely result in more information than will be provided by choosing five organisms, the statement said.


"If we are prepared to assume that the most informative set is the one with the greatest evolutionary divergence, the problem of which species to sequence next can be solved by observing the length of the branches that separate the unsequenced species from those that have already had their genomes sequenced, and choosing the organism that's separated from the others by the longest sequence of branches," Pardi said in the statement.


Although the strategy developed by Pardi and co-author Nick Goldman only takes into account evolutionary divergence, it can be expanded to include other factors, such as the cost of sequencing or the economic importance of an organism, the statement said.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.